Trial Profile
The Effect of CTLA-4/PD-L1 Blockade Following Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC Using Durvalumab (MEDI4736) and Tremelimumab
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 01 Dec 2023 Status changed from recruiting to active, no longer recruiting.
- 01 Dec 2023 Planned End Date changed from 1 Jan 2024 to 1 Dec 2024.
- 01 Dec 2023 Planned primary completion date changed from 1 Jan 2024 to 1 Sep 2024.